A leading pharmaceutical company announced a novel meloxicam injection which is approved for the treatment of moderate to severe pain in many surgical techniques. It can be used as monotherapy (alone) or along with non-nonsteroidal anti-inflammatory drugs (NSAIDs) in adults.

Meloxicam injection is a NSAID with anti-inflammatory, analgesic, anti-inflammatory, and antipyretic advantages. It is a formulation of 30 mg per mL in single-dose vials. It can be used as a once-daily intravenous bolus injection. To minimize the risk of renal toxicity, the patients must be well hydrated before its administration.

This injection is not suggested in the need to quick analgesia because it offers delayed onset of analgesia. As per 2 clinical studies, the pain relief was found to be 2-3 hours on an average, after its administration. In certain patients, administration of a short-acting, non-NSAID, immediate-release analgesic may be used for suitable analgesia over the 24-hour dosing interval.

Considering its safety profile, adverse reactions like constipation, augmented gamma-glutamyl transferase, and anemia were commonly observed. This meloxicam injection carries a Boxed Warning describing about the possible risk of associated serious CV and GI events. 

By June, 2020, a full commercial launch of this meloxicam injection is anticipated.